Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

299 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Could PD-1/PDL1 immune checkpoints be linked to HLA signature?
Correale P, Saladino RE, Nardone V, Giannicola R, Agostino R, Pirtoli L, Caraglia M, Botta C, Tagliaferri P. Correale P, et al. Among authors: tagliaferri p. Immunotherapy. 2019 Dec;11(18):1523-1526. doi: 10.2217/imt-2019-0160. Epub 2019 Dec 9. Immunotherapy. 2019. PMID: 31865873 No abstract available.
Alpha-interferon and its effects on signalling pathways within cells.
Caraglia M, Vitale G, Marra M, Budillon A, Tagliaferri P, Abbruzzese A. Caraglia M, et al. Among authors: tagliaferri p. Curr Protein Pept Sci. 2004 Dec;5(6):475-85. doi: 10.2174/1389203043379378. Curr Protein Pept Sci. 2004. PMID: 15581417 Review.
The farnesyltransferase inhibitor R115777 (ZARNESTRA) enhances the pro-apoptotic activity of interferon-alpha through the inhibition of multiple survival pathways.
Caraglia M, Marra M, Viscomi C, D'Alessandro AM, Budillon A, Meo G, Arra C, Barbieri A, Rapp UR, Baldi A, Tassone P, Venuta S, Abbruzzese A, Tagliaferri P. Caraglia M, et al. Among authors: tagliaferri p. Int J Cancer. 2007 Nov 15;121(10):2317-30. doi: 10.1002/ijc.22964. Int J Cancer. 2007. PMID: 17657738
Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial).
Correale P, Tagliaferri P, Fioravanti A, Del Vecchio MT, Remondo C, Montagnani F, Rotundo MS, Ginanneschi C, Martellucci I, Francini E, Cusi MG, Tassone P, Francini G. Correale P, et al. Among authors: tagliaferri p. Clin Cancer Res. 2008 Jul 1;14(13):4192-9. doi: 10.1158/1078-0432.CCR-07-5278. Clin Cancer Res. 2008. PMID: 18593999 Clinical Trial.
In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor.
Neri P, Tagliaferri P, Di Martino MT, Calimeri T, Amodio N, Bulotta A, Ventura M, Eramo PO, Viscomi C, Arbitrio M, Rossi M, Caraglia M, Munshi NC, Anderson KC, Tassone P. Neri P, et al. Among authors: tagliaferri p. Br J Haematol. 2008 Nov;143(4):520-31. doi: 10.1111/j.1365-2141.2008.07387.x. Br J Haematol. 2008. PMID: 18986388 Free article.
Second-line treatment of non small cell lung cancer by biweekly gemcitabine and docetaxel +/- granulocyte-macrophage colony stimulating factor and low dose aldesleukine.
Correale P, Tindara Miano S, Remondo C, Migali C, Rotundo MS, Macrì P, Tagliaferri P, Caraglia M, Gotti G, Francini G. Correale P, et al. Among authors: tagliaferri p. Cancer Biol Ther. 2009 Mar 15;8(6):497-502. doi: 10.4161/cbt.8.6.7593. Epub 2009 Mar 15. Cancer Biol Ther. 2009. PMID: 19242101 Free article. Clinical Trial.
299 results